My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...
Hosted on MSN23h
NICE green lights two blood cancer therapies for NHS useBMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...
We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other stocks kick off ...
Cryptopolitan on MSN7d
Nancy Pelosi makes Tempus AI’s stock a top performer after buying call optionsNancy Pelosi just made Tempus AI (TEM) the stock of the moment. The former Speaker of the House quietly purchased 50 call ...
Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...
Tempus AI shares soared to an all-time high Thursday as the tech firm announced a collaboration with the nonprofit Institute ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback